Country: South Korea

GBCC, formerly known as Interpark Bioconvergence Corporation, is one of the earliest organizations developing patient derived organoids (PDOs) in global scale. We have over 500 PDOs from lung, gastric and colorectal cancer patients and are also developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our CRISPR-based PDO platform. Beyond cancer, GBCC is conducting research on brain organoid from human iPSC for disease modeling and regenerative medicine. In addition, we are developing human derived probiotics not only as health functional foods but also therapeutic agents through functional evaluation using our colon PDOs. | Gradiant Bioconvergence (GBCC) is one of the earliest organizations developing patient derived cancer organoids (PDOs) in global scale. We have built Asia’s largest repository of PDOs with next-generation sequencing of over 600 models from lung, gastric and colorectal cancer patients. In addition, we are developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC is establishing brain organoids from human iPSCs for disease modeling and regenerative medicine. | Gradiant Bioconvergence (GBCC) is one of the earliest organizations developing patient derived cancer organoids (PDOs) in global scale. We have built one of Asia’s largest repository of PDOs with next-generation sequencing of over 800 models from lung, gastric and colorectal cancer patients. In addition, we are developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC is establishing brain organoids from human iPSCs for disease modeling and regenerative medicine. | xxx